Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Graefen

Showing results (261-270 of 918) with videos related to

Pageof 92
Sort By:
Scientific Reports|February 26, 2020
Subcellular Compartmentalization of Survivin is Associated with Biological Aggressiveness and Prognosis in Prostate CancerJan K Hennigs, Sarah Minner, Pierre Tennstedt, et al.
Urologic Oncology|October 9, 2025
Use of staging in intermediate-risk prostate cancer: A real-world data analysisBen Frederik Hartwieg, Tobias Maurer, Christopher Kniep, et al.
Urologic Oncology|July 1, 2015
Assessing the clinical benefit of a nomogram to predict specimen-confined disease at radical prostatectomy in patients with high-risk prostate cancer: An external validationJens Hansen, Andreas Becker, Luis A Kluth, et al.
The Prostate|March 24, 2018
Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrenceRaisa S Pompe, Philipp Gild, Pierre I Karakiewicz, et al.
Cancer|October 15, 2008
Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lowerJochen Walz, Alexander Haese, Vincenzo Scattoni, et al.
Urology|November 10, 2019
Rectal Swabs for Detecting Multidrug Resistant Bacteria Prior to Transrectal Prostate Fusion Biopsy: A Prospective Evaluation of Risk Factor Screening and Microbiologic FindingsChristoph Würnschimmel, Luis Busto Martin, Sami-Ramzi Leyh-Bannurah, et al.
BJU International|January 7, 2015
Effect of surgical approach on erectile function recovery following bilateral nerve-sparing radical prostatectomy: an evaluation utilising data from a randomised, double-blind, double-dummy multicentre trial of tadalafil vs placeboJens-Uwe Stolzenburg, Markus Graefen, Christian Kriegel, et al.
Urologic Oncology|November 26, 2015
Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancerKatharina Boehm, Jonas Schiffmann, Zhe Tian, et al.
World Journal of Urology|July 29, 2015
True targeting-derived prostate biopsy: HistoScanning™ remained inadequate despite advanced technical effortsJonas Schiffmann, Gisa Mehring, Pierre Tennstedt, et al.
Minerva Urology and Nephrology|December 21, 2023
Prevalence of bilateral loco-regional spread in unilateral pelvic PSMA PET positive recurrent prostate cancerFrancesca Ambrosini, Fabian Falkenbach, Lars Budaeus, et al.
Pageof 92

Showing results (261-270 of 918) with videos related to

Sort By:
Pageof 92
Scientific Reports|February 26, 2020
Subcellular Compartmentalization of Survivin is Associated with Biological Aggressiveness and Prognosis in Prostate CancerJan K Hennigs, Sarah Minner, Pierre Tennstedt, et al.
Urologic Oncology|October 9, 2025
Use of staging in intermediate-risk prostate cancer: A real-world data analysisBen Frederik Hartwieg, Tobias Maurer, Christopher Kniep, et al.
Urologic Oncology|July 1, 2015
Assessing the clinical benefit of a nomogram to predict specimen-confined disease at radical prostatectomy in patients with high-risk prostate cancer: An external validationJens Hansen, Andreas Becker, Luis A Kluth, et al.
The Prostate|March 24, 2018
Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrenceRaisa S Pompe, Philipp Gild, Pierre I Karakiewicz, et al.
Cancer|October 15, 2008
Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lowerJochen Walz, Alexander Haese, Vincenzo Scattoni, et al.
Urology|November 10, 2019
Rectal Swabs for Detecting Multidrug Resistant Bacteria Prior to Transrectal Prostate Fusion Biopsy: A Prospective Evaluation of Risk Factor Screening and Microbiologic FindingsChristoph Würnschimmel, Luis Busto Martin, Sami-Ramzi Leyh-Bannurah, et al.
BJU International|January 7, 2015
Effect of surgical approach on erectile function recovery following bilateral nerve-sparing radical prostatectomy: an evaluation utilising data from a randomised, double-blind, double-dummy multicentre trial of tadalafil vs placeboJens-Uwe Stolzenburg, Markus Graefen, Christian Kriegel, et al.
Urologic Oncology|November 26, 2015
Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancerKatharina Boehm, Jonas Schiffmann, Zhe Tian, et al.
World Journal of Urology|July 29, 2015
True targeting-derived prostate biopsy: HistoScanning™ remained inadequate despite advanced technical effortsJonas Schiffmann, Gisa Mehring, Pierre Tennstedt, et al.
Minerva Urology and Nephrology|December 21, 2023
Prevalence of bilateral loco-regional spread in unilateral pelvic PSMA PET positive recurrent prostate cancerFrancesca Ambrosini, Fabian Falkenbach, Lars Budaeus, et al.
Pageof 92